Granissetrom Hikma

Granissetrom Hikma is an intravenous solution containing the active ingredient granisetron. It is supplied in a dosage form intended for injection and is classified as a 5-HT3 receptor antagonist. The product is marketed in the European Union and is available by prescription only. Granisetron works by selectively blocking peripheral and central serotonin receptors to help control nausea and vomiting associated with chemotherapy and surgery.

Granissetrom Hikma is prescribed to manage nausea and vomiting in several clinical settings. It is commonly used for:

- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Prevention of postoperative nausea and vomiting (PONV). - Management of radiation‑induced nausea and vomiting. - Adjunct therapy for nausea related to diagnostic procedures involving contrast agents. - Use in patients who have not responded adequately to other antiemetic regimens.

Granisetrom Hikma may cause a range of side effects, most of which are mild to moderate in severity.

Common: - Headache - Constipation - Fatigue - Dizziness - Injection site discomfort

Serious: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmia or QT prolongation - Severe constipation leading to bowel obstruction - Persistent vomiting despite therapy

Before using Granissetrom Hikma, certain precautions should be considered to ensure safe administration.

- Assess patient history for cardiac disease, especially prolonged QT interval. - Use caution in patients with hepatic impairment, as metabolism may be reduced. - Monitor for signs of severe constipation or bowel obstruction. - Evaluate for hypersensitivity to granisetron or any formulation components. - Consider dose adjustment in elderly patients. - Avoid use in patients with known hypersensitivity to other 5‑HT3 antagonists.

Granisetrom Hikma can interact with other medications, potentially altering its efficacy or safety profile.

Avoid: - Concurrent use with other 5‑HT3 antagonists, which may increase the risk of cardiac effects. - Co‑administration with drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution: - Anticholinergic agents that may exacerbate constipation. - CYP3A4 inhibitors or inducers, which could affect granisetron metabolism. - Medications that cause electrolyte disturbances, such as diuretics, which may predispose to cardiac arrhythmias.